查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1928631

周邊動脈藥物塗層球囊導管市場（按塗層類型、應用領域、最終用戶和分銷管道分類），全球預測（2026-2032年）

Peripheral DCB Catheter Market by Coating Type, Application Area, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，周邊 DCB 導管市場價值將達到 13.2 億美元，到 2026 年將成長至 14.1 億美元，到 2032 年將達到 23.5 億美元，複合年成長率為 8.47%。

關鍵市場統計數據
基準年 2025 13.2億美元
預計年份：2026年 14.1億美元
預測年份 2032 23.5億美元
複合年成長率 (%) 8.47%

周邊血管藥物塗層球囊導管：作為血管和透析通路護理路徑發展中的核心技術的策略概述

周邊藥物洗脫球囊導管融合了介入性心臟病學、血管外科和醫療系統經濟學，是治療周邊動脈疾病和透析通路功能障礙的重要工具。這些裝置結合了傳統血管成形術的機械優勢和局部藥物輸送至血管壁的功能，旨在減少血管再阻塞，同時最大限度地減少對支架等永久性植入的需求。隨著醫療系統致力於改善治療效果並維持長期血管通路，周邊藥物洗脫球囊導管已從一種小眾工具發展成為現代腔內治療的重要組成部分。

周邊藥物塗層球囊導管治療的變革性變化正在重新定義其臨床應用、技術選擇和價值預期。

過去十年，周邊藥物塗層球囊（DCB）導管領域經歷了變革性的變化，這主要得益於臨床證據、器械創新以及相關人員期望的轉變。 DCB最初被定位為股膕動脈疾病的首選治療方法，但隨著數據的積累、指南的更新以及醫生技能的提高，其應用範圍已擴展至更廣泛的周邊動脈疾病和透析通路手術。此外，糖尿病、慢性腎臟病盛行率的上升以及人口老化等因素導致周邊血管介入治療的頻率和複雜性不斷增加，也推動了這一轉變。

美國關稅政策轉變的累積影響：重塑成本結構、籌資策略與競爭地位

美國不斷變化的關稅制度，包括預計2025年左右生效的措施，正對周邊藥物塗層球囊（DCB）導管價值鏈產生累積影響。許多DCB組件，包括特種聚合物、原料藥和精密設計的導管組件，都是透過全球分散的供應鏈網路採購或生產的。對進口原料或成品徵收關稅可能會增加生產成本、壓縮利潤率，或提高醫院、門診手術中心和專科診所的採購價格。

透過對應用程式、塗料、終端用戶和分銷管道的詳細細分分析，揭示了DCB採用的細微促進因素。

要了解周邊藥物塗層球囊（DCB）導管市場，需要深入了解應用、塗層技術、終端用戶和分銷模式如何相互作用，從而塑造市場需求並推動創新。從應用角度來看，有三個主要領域正在推動臨床應用：膝下介入治療、透析通路維護和股膕動脈介入治療。在膝下介入治療中，跗弓介入治療和脛動脈介入治療各自面臨不同的臨床挑戰。足弓手術通常旨在恢復嚴重肢體缺血患者的血流。由於血管直徑較小且病灶瀰漫，導管的輸送性、可追蹤性和精準的藥物傳遞至關重要。相較之下，脛動脈介入治療通常針對較長的鈣化病變，需要結合血管準備和可靠的藥物輸送，以減少血管再阻塞並避免經股動脈截肢。

美洲、歐洲、中東和非洲以及亞太地區的區域觀點凸顯了不同的採用路徑和戰略重點。

區域趨勢對周邊血管藥物塗層球囊（DCB）導管的採用、評估和報銷方式有著深遠的影響。在美洲，先進的醫療保健體係以及周邊動脈疾病、糖尿病和慢性腎臟病的高發病率，極大地推動了臨床創新和早期技術應用。尤其值得一提的是，美國在臨床證據的產生、手術標準的發展以及對全球DCB技術認知的影響方面發揮核心作用。該地區的醫院和門診機構積極採用DCB導管進行股膕動脈、膝下動脈和透析通路介入治療，但其應用進展可能因支付方政策、地理獎勵和不斷變化的收費系統而有所不同。

主要企業利用塗層創新、臨床證據和綜合支持，塑造競爭激烈的DCB市場。

周邊藥物塗層球囊（DCB）導管的競爭格局呈現出兩大巨頭並存的局面：既有成熟的跨國醫療設備公司，也有專注於血管介入治療的創新企業，它們各自擁有獨特的策略來實現產品差異化。主要企業通常擁有涵蓋球囊、支架、動脈粥狀硬化斑塊切除術裝置和通路工具等廣泛的產品系列組合，將DCB定位為綜合解決方案的一部分，而非獨立產品。這種整合式方法使它們能夠利用配套工具和一致的手術流程，支援諸如慢性完全閉塞血管再通、膝下多節段血管重建以及復發性透析通路介入等複雜手術。

為應對藥物塗層球囊（DCB）不斷變化的臨床和經濟現實，制定調整產品系列、供應鏈和夥伴關係的實用策略。

周邊藥物塗層球囊（DCB）導管領域的領導者必須將複雜的臨床和經濟因素轉化為具體可行的策略。其中一項重點工作是深化在關鍵應用領域的參與，例如膝下介入治療、透析通路維護和股膕動脈介入治療。產品特性、訓練項目和實證醫學證據的產生必須根據各個領域的實際情況進行最佳化。例如，針對足背動脈弓和脛動脈介入治療的專用球囊外形和相關訓練可以幫助臨床醫生處理即使是最小的病變血管。此外，針對動靜脈瘻管和動靜脈移植介入治療的專項支援可以將DCB定位為長期透析通路管理的核心工具。

一種整合了關於藥物塗層球囊導管的臨床、監管和競爭資訊的穩健的多源調查方法

本執行分析的調查方法整合了多種互補途徑，旨在全面掌握周邊藥物塗層球囊（DCB）導管環境的複雜性。研究以系統性回顧同儕審查的臨床文獻為基礎，重點在於周邊動脈疾病、膝下血管再灌注、股膕動脈介入治療、透析通路維持等方面的研究。研究特別關注評估紫杉醇和Sirolimus塗層球囊的臨床試驗和註冊研究，其終點分析包括主要通暢率、目標病變血管重建、肢體挽救率和通路耐久性。這些依證使我們能夠深入了解不同塗層技術在不同病變類型和患者群體中的表現。

臨床、監管和經濟因素共同凸顯了周邊藥物塗層球囊導管的戰略重要性。

周邊藥物釋放型球囊導管已從專門的治療工具發展成為現代周邊動脈和透析通路管理的核心組成部分，這得益於不斷累積的臨床證據和持續的技術改進。其獨特的機械擴張管腔與局部藥物遞送相結合的能力，為解決持續存在的血管再阻塞難題提供了強力的方案，尤其是在膝下動脈、股膕動脈區域和動靜脈通路等複雜解剖區域。隨著臨床醫生和醫療系統日益關注肢體保護、透析通路的持久性和減少再次干預的需求，藥物洗脫球囊導管在治療流程中發揮越來越重要的策略作用。

然而，這些設備運作的環境正變得越來越複雜：地區不同的監管要求、不斷變化的安全觀念以及不同的報銷框架正在重塑 DCB 的應用方式和應用地點。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 周邊動脈藥物塗層球囊導管市場（依塗層類型分類）

  • 紫杉醇塗層
  • Sirolimus塗層

9. 周邊動脈藥物塗層球囊導管市場（依應用分類）

  • 膝下介入治療
    • 足弓干預
    • 脛動脈介入治療
  • 維持透析通路
    • 動靜脈瘻管
    • 動靜脈移植
  • 股膕動脈介入治療
    • 慢性完全閉塞
    • 新病變
    • 支架內血管再阻塞

10. 依最終使用者分類的周邊動脈藥物塗層球囊導管市場

  • 門診手術中心
  • 醫院
  • 專科診所

11. 周邊動脈藥物塗層球囊導管市場（依分銷管道分類）

  • 直銷
  • 經銷商

12. 周邊動脈藥物塗層球囊導管市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

13. 周邊動脈藥物塗層球囊導管市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各國周邊動脈藥物塗層球囊導管市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

15. 美國周邊動脈藥物塗層球囊導管市場

第16章 中國周邊動脈藥物塗層球囊導管市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Acotec Scientific Co., Ltd.
  • Alea Medical GmbH
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Biotronik SE & Co. KG
  • Boston Scientific Corporation
  • Cardionovum GmbH
  • CeloNova BioSciences, Inc.
  • Concept Medical, Inc.
  • Cook Medical LLC
  • Cordis US Corp.
  • Hexacath Limited
  • Koninklijke Philips NV
  • Lepu Medical Technology（Beijing）Co., Ltd.
  • Medtronic plc
  • Meril Life Sciences Pvt. Ltd.
  • Mermaid Medical AS
  • MicroPort Medical（Group）Co., Ltd.
  • OrbusNeich Medical Group Holdings Limited
  • QT Vascular Ltd.
  • Reflow Medical, Inc.
  • Spectranetics Corporation
  • Svelte Medical Systems, Inc.
  • Terumo Corporation
  • Zhejiang Barty Medical Technology Co., Ltd.
Product Code: MRR-92740D85F07C

The Peripheral DCB Catheter Market was valued at USD 1.32 billion in 2025 and is projected to grow to USD 1.41 billion in 2026, with a CAGR of 8.47%, reaching USD 2.35 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.32 billion
Estimated Year [2026] USD 1.41 billion
Forecast Year [2032] USD 2.35 billion
CAGR (%) 8.47%

Strategic overview of peripheral DCB catheters as a pivotal technology in evolving vascular and dialysis access care pathways

Peripheral drug-coated balloon catheters sit at the intersection of interventional cardiology, vascular surgery, and health-system economics, representing a critical tool in the treatment of peripheral arterial disease and dialysis access dysfunction. These devices combine the mechanical benefits of conventional angioplasty with localized drug delivery to the vessel wall, aiming to reduce restenosis while minimizing the need for permanent implants such as stents. As health systems strive to improve outcomes and preserve long-term vascular access, peripheral DCB catheters have evolved from niche tools to essential components of contemporary endovascular therapy.

The growing clinical emphasis on limb preservation, reduction of repeat interventions, and improvement of dialysis access patency has accelerated interest in DCB-based strategies. High-risk patient populations, including those with diabetes and chronic kidney disease, stand to benefit from technologies that can effectively treat complex lesions in challenging vascular territories below the knee, within the femoropopliteal segment, or in arteriovenous fistulas and grafts used for hemodialysis. Clinicians and payers are increasingly focused on therapies that demonstrate durable patency, reduced reintervention, and improved quality of life, creating a strong rationale for the use of DCB catheters when supported by robust evidence.

At the same time, technology developers have responded with innovations in coating formulations, balloon designs, and delivery systems aimed at improving drug transfer, minimizing downstream particulate, and tailoring performance to specific lesion types. Paclitaxel-coated balloons remain well-established in many indications, backed by years of clinical experience, while sirolimus-coated platforms are gaining momentum as developers seek to address safety perceptions, broaden indications, and optimize biological responses. These clinical and technological dynamics are unfolding against a backdrop of regulatory scrutiny, pricing pressure, and emerging tariffs, making strategic insight essential for stakeholders seeking to navigate this complex and rapidly evolving landscape.

Transformational shifts redefining clinical use, technology choices, and value expectations in peripheral DCB catheter therapy

Over the past decade, the landscape for peripheral DCB catheters has undergone transformative shifts driven by clinical evidence, device innovation, and evolving stakeholder expectations. Initially, DCBs were positioned as a specialized option for select femoropopliteal lesions; however, accumulating data, guideline evolution, and increasing physician familiarity have expanded their role across broader peripheral arterial disease and dialysis access scenarios. This shift has been reinforced by the rising prevalence of diabetes, chronic kidney disease, and an aging population, all of which contribute to more frequent and complex peripheral vascular interventions.

A notable transformation has been the move from a device-centric to an outcomes-centric ecosystem. Hospitals, ambulatory surgical centers, and specialty clinics are not merely evaluating DCBs on technical specifications, but increasingly on long-term patency, reduction in target lesion revascularization, and impact on limb salvage or dialysis access longevity. As value-based care and bundled payment models gain traction in various health systems, purchasing decisions are tied more closely to procedure durability and downstream resource use. This environment favors technologies that can credibly demonstrate durable benefit and robust real-world performance, pushing manufacturers to invest in high-quality, long-term clinical data and post-market surveillance.

Another significant shift concerns safety perception and regulatory rigor. The industry responded to prior debates around drug-coated device safety with extensive re-analyses, new trials, and more transparent reporting. This has encouraged a more nuanced understanding of risk-benefit profiles, particularly in patients with advanced comorbidities. Regulatory authorities in major regions now expect comprehensive evidence packages, including subgroup analyses for complex lesion subsets such as below-the-knee disease, chronic total occlusions, and in-stent restenosis. As a result, clinical development strategies have become more sophisticated, with focused registries and pragmatic trials that better reflect real-world practice.

Technological innovation has also reshaped competitive dynamics. Coating science has advanced from early-generation formulations toward more controlled drug release, improved excipients, and enhanced balloon platforms designed for tortuous anatomy and calcified lesions. While paclitaxel-based systems maintain a strong incumbent position, there is a clear trend toward diversification, with sirolimus-coated alternatives emerging in response to clinician demand for options perceived as biologically distinct. This evolution has intensified competition and opened space for differentiated value propositions based on lesion specificity, deliverability, safety profile, and compatibility with complementary tools.

In parallel, care delivery is shifting from inpatient to outpatient and office-based settings, powered by improved device profiles, growing operator expertise, and payer policies that favor cost-effective sites of service. Ambulatory surgical centers and specialty clinics are playing a larger role in peripheral interventions, driving the need for logistics-friendly distribution models, streamlined inventory management, and service support tailored to high-throughput environments. These systemic changes, combined with macroeconomic pressures and renewed focus on health equity, are redefining where and how peripheral DCB procedures are performed, and which stakeholders exert the greatest influence on purchasing decisions.

Cumulative impact of evolving United States tariff policies reshaping costs, sourcing strategies, and competitive positioning

The evolving tariff framework in the United States, including measures anticipated around 2025, is exerting a cumulative impact across the peripheral DCB catheter value chain. Many DCB components, such as specialty polymers, drug substances, and precision-engineered catheter parts, are sourced or manufactured through globally distributed supply networks. When tariffs are applied to imported inputs or finished devices, they can raise production costs, compress margins, or elevate acquisition prices for hospitals, ambulatory surgical centers, and specialty clinics.

Manufacturers are reacting by re-examining their sourcing strategies, considering nearshoring or dual-sourcing for critical materials, and negotiating revised terms with suppliers. Some are exploring localized assembly or packaging in the United States to mitigate tariff exposure, although such moves require capital investment and operational restructuring. These shifts can lengthen lead times or introduce transitional supply risks, which must be carefully managed to ensure continuity of DCB availability for complex interventions such as below-the-knee revascularization, femoropopliteal procedures, and dialysis access maintenance.

For providers, the tariff environment contributes to intensifying cost pressure. Device committees and procurement teams are increasingly attentive to total procedural cost, especially in outpatient settings where reimbursement may be more constrained. If tariffs translate into higher unit prices, institutions may push for volume-based discounts, standardization on a more limited set of DCB platforms, or stricter clinical criteria for use in specific lesion cohorts. In some cases, this can slow the adoption of newer coating types or niche indications until health-economic benefits are clearly established.

At the same time, tariffs intersect with broader policy initiatives aimed at strengthening domestic manufacturing and supply resilience. Companies that proactively adapt may gain a strategic advantage if they can demonstrate supply reliability, stable pricing, and responsiveness to U.S. regulatory and reimbursement requirements. Over the longer term, the cumulative effect of tariffs may reshape competitive landscapes by favoring organizations with diversified manufacturing footprints, robust trade compliance capabilities, and the financial flexibility to absorb short-term cost fluctuations while sustaining investment in innovation.

Despite these headwinds, opportunities arise for differentiated strategies. Some stakeholders are exploring value-based purchasing agreements that link reimbursement or pricing to patient outcomes, thus softening the immediate impact of tariffs by emphasizing longer-term cost savings from reduced reinterventions. Others are prioritizing DCB adoption in high-impact segments, such as limb-threatening ischemia or threatened dialysis access, where clinical benefit and cost avoidance are most tangible. In this environment, nuanced understanding of tariff implications and their interaction with clinical and economic value propositions becomes an important success factor for both manufacturers and providers.

Deep segmentation insights across applications, coatings, end users, and channels reveal nuanced drivers of DCB adoption

Understanding the peripheral DCB catheter market requires a detailed view of how applications, coating technologies, end users, and distribution models interact to shape demand and innovation. From an application standpoint, three broad areas drive clinical utilization: below knee intervention, dialysis access maintenance, and femoropopliteal intervention. Within below knee intervention, pedal arch intervention and tibial artery intervention represent distinct clinical challenges. Pedal arch procedures are typically focused on restoring perfusion in patients with critical limb-threatening ischemia, where vessel caliber is small and disease burden diffuse, making deliverability, trackability, and precise drug transfer crucial. Tibial artery interventions, by contrast, often deal with long, calcified segments that require a combination of vessel preparation and reliable drug delivery to reduce restenosis and avoid major amputation.

Dialysis access maintenance forms another important application cluster, encompassing both arteriovenous fistula and arteriovenous graft interventions. In these settings, DCBs are increasingly used to manage recurrent stenosis at anastomotic sites or within the access circuit, with the goal of extending access patency and reducing the frequency of interventions. Because dialysis patients undergo repeated procedures over many years, devices used in arteriovenous fistula and arteriovenous graft settings must demonstrate consistent performance, predictable safety, and compatibility with other access management tools. This drives demand for balloons that offer reliable drug coating integrity through multiple inflations and that can be navigated efficiently across scarred or previously treated segments.

Femoropopliteal intervention represents a third pillar and includes chronic total occlusion, de novo lesions, and in-stent restenosis. Chronic total occlusions often require advanced crossing tools and meticulous vessel preparation before DCB application, highlighting the value of integrated product portfolios and strong procedural support. De novo lesions offer a broader canvas for demonstrating the stand-alone potential of DCBs versus stents, especially when long-term patency and reduced need for permanent implants are prioritized. In-stent restenosis management, meanwhile, leverages DCBs as a means of addressing neo-intimal hyperplasia without adding further metal layers, making performance in this niche a key differentiator among competing platforms.

Coating type is another central dimension, with paclitaxel-coated and sirolimus-coated DCBs each occupying distinct strategic positions. Paclitaxel-coated devices benefit from extensive historical data, a wide range of indications, and operator familiarity; they are frequently used across femoropopliteal and dialysis access interventions where their antiproliferative effect has been well-characterized. Sirolimus-coated devices, on the other hand, are emerging as attractive alternatives in markets and clinical communities that value a different pharmacological mechanism, potentially more controlled drug release, and evolving evidence on safety and efficacy. The interplay between these coating types encourages portfolio diversification, with some providers adopting a mixed strategy that aligns specific devices with lesion complexity, patient risk profile, and institutional protocols.

End user dynamics further refine market behavior. Hospitals remain central, particularly large tertiary centers that handle complex chronic total occlusions, multilevel disease, and high-risk dialysis access cases. These facilities often drive early adoption of novel DCB technologies, participate in clinical studies, and influence guideline development. Ambulatory surgical centers are gaining traction as preferred sites for select femoropopliteal and below-the-knee interventions, leveraging lower overhead and efficient throughput. Their purchasing criteria emphasize procedural efficiency, device reliability, and cost-effectiveness, which in turn incentivize vendors to provide robust training and responsive service. Specialty clinics, including office-based laboratories, contribute by expanding access to peripheral interventions closer to patients' communities, often favoring streamlined product lines and dependable supply arrangements.

Finally, distribution channel strategies, spanning direct sales and distributor-based models, shape how products reach these diverse end users. Direct sales approaches allow manufacturers to build strong relationships with high-volume hospitals and specialty centers, offering tailored clinical education, on-site case support, and rapid feedback loops for product refinement. Distributor-led models can extend reach into smaller facilities and emerging markets, providing localized inventory management and market-specific insights. The optimal mix of distribution approaches varies by region and customer profile, but in all cases, alignment between commercial strategy and the distinct needs of below knee, dialysis access, and femoropopliteal interventions is essential to capture growth opportunities and sustain clinician loyalty.

Regional perspectives across Americas, EMEA, and Asia-Pacific highlight diverse adoption pathways and strategic priorities

Regional dynamics exert a profound influence on how peripheral DCB catheters are adopted, evaluated, and reimbursed. In the Americas, clinical innovation and early technology uptake are strongly shaped by sophisticated health systems and a high burden of peripheral arterial disease, diabetes, and chronic kidney disease. The United States, in particular, plays a central role in generating clinical evidence, setting procedural standards, and influencing global perceptions of DCB technologies. Hospitals and outpatient facilities in this region are active in adopting devices for femoropopliteal, below-the-knee, and dialysis access interventions, though adoption trajectories can vary depending on payer policies, site-of-service incentives, and evolving tariff structures.

Throughout the broader Americas, including Canada and Latin American markets, access to DCB technology is influenced by variations in public and private reimbursement, procurement practices, and infrastructure. Larger urban centers are often able to offer advanced DCB interventions, while more resource-constrained settings may rely on a narrower device portfolio and prioritize cost-sensitive options. In this environment, local training, registry participation, and partnerships with regional distributors become critical enablers of responsible and sustainable DCB expansion.

In Europe, Middle East, and Africa, the environment is characterized by diverse regulatory pathways, distinct health-system models, and varying levels of interventional capacity. Many European countries have a tradition of rigorous clinical evaluation and structured guideline integration, which can support the adoption of both paclitaxel- and sirolimus-coated balloons when supported by strong evidence. Reimbursement frameworks often emphasize cost-effectiveness and long-term outcomes, encouraging the use of DCB technology in scenarios where reduced reintervention and improved limb or access preservation can be clearly demonstrated. Meanwhile, in parts of the Middle East and Africa, adoption levels may be more heterogeneous, with leading tertiary centers embracing advanced DCB procedures and other facilities still building basic endovascular capabilities.

Across this broad region, procurement often occurs through tenders and centralized purchasing bodies, requiring manufacturers to offer competitive pricing and robust service support. The presence of experienced interventionalists, national vascular societies, and regional training hubs can accelerate skill transfer and promote consistent use of DCBs in femoropopliteal, below-the-knee, and dialysis access applications. At the same time, disparities in healthcare funding and infrastructure demand flexible commercial models and thoughtful product positioning to ensure that innovation reaches patients who would benefit most.

Asia-Pacific presents a different, rapidly evolving profile for peripheral DCB catheters. Many countries in this region, including those with large populations and rising rates of diabetes and chronic kidney disease, are experiencing increased demand for peripheral interventions. Expanding healthcare infrastructure, investments in catheterization laboratories, and growing specialist training programs are all contributing to a broader base of interventional expertise. In this context, DCB adoption often starts in top-tier academic and referral centers before cascading into secondary hospitals and high-volume clinics.

Regulatory and reimbursement environments across Asia-Pacific are varied, with some countries implementing relatively streamlined device approval processes and others maintaining more conservative policies. Pricing sensitivity is an important factor, and decisions about whether to introduce paclitaxel-coated or sirolimus-coated platforms may hinge on local cost constraints, clinical evidence preferences, and strategic partnerships with regional distributors. Additionally, the prominence of outpatient care models is increasing in several markets, creating new opportunities for DCB use in ambulatory surgical centers and specialized vascular clinics. Collectively, these regional differences underscore the need for tailored strategies that align product portfolios, pricing, and education with the specific needs and constraints of each geography.

Leading companies leverage coating innovation, clinical evidence, and integrated support to shape competitive DCB landscapes

The competitive environment for peripheral DCB catheters is marked by a combination of established multinational device firms and specialized vascular innovators, each pursuing distinct strategies to differentiate their offerings. Leading companies typically maintain broad product portfolios that span balloons, stents, atherectomy devices, and access tools, positioning DCBs as part of a comprehensive solution rather than stand-alone products. This integrated approach allows them to support complex procedures such as chronic total occlusion recanalization, below-the-knee multilevel revascularization, and recurrent dialysis access interventions with complementary tools and consistent procedural workflows.

A central axis of differentiation is coating technology and associated clinical evidence. Companies with mature paclitaxel-coated platforms emphasize their extensive track record, robust prospective trial data, and long-term follow-up across femoropopliteal and other peripheral indications. These firms often invest heavily in post-market registries and real-world evidence initiatives to demonstrate performance in diverse patient populations, including those with heavily calcified lesions, long segment disease, or prior stent placement. At the same time, a growing cohort of manufacturers is focusing on sirolimus-coated balloons, seeking to capitalize on the broader industry shift toward sirolimus-based drug delivery in coronary and peripheral applications. These companies highlight biocompatibility, controlled elution profiles, and emerging clinical data as key components of their value proposition.

Customer engagement strategies further distinguish key players. Many leading companies deploy specialized sales and clinical support teams who are deeply familiar with peripheral arterial disease, critical limb-threatening ischemia, and dialysis access management. They provide on-site case support, physician proctoring for new techniques, and educational programs that cover lesion assessment, vessel preparation, DCB deployment, and adjunctive therapies. Such close collaboration not only aids device adoption but also generates feedback that feeds into iterative product improvements, new balloon sizes, or lesion-specific designs.

Strategic partnerships and portfolio expansions are also shaping the competitive landscape. Some companies are pursuing collaborations with imaging and navigation technology providers to integrate intravascular ultrasound or other tools that optimize DCB use. Others are acquiring or partnering with firms specializing in vessel preparation devices, such as atherectomy or specialty balloons, to reinforce the link between optimal lesion preparation and DCB outcomes. These initiatives align with a procedural mindset, in which the entire intervention-from access to closure-is optimized to support durable results.

From an operational standpoint, leading players are investing in manufacturing resilience, quality systems, and supply chain flexibility to cope with regulatory requirements and trade uncertainties. Facilities are being upgraded to support advanced coating technologies, stringent particle-shedding controls, and scalability for global distribution. Companies that can reliably supply hospitals, ambulatory surgical centers, and specialty clinics with consistent product quality and timely deliveries gain a tangible competitive advantage, especially in markets where procedural volumes are rising and disruptions can impact patient care.

In this dynamic environment, competitive success hinges on the ability to balance innovation with evidence, and technical differentiation with practical usability. Organizations that integrate meaningful clinical data, lesion-specific design, robust training, and agile supply capabilities are best positioned to capture clinician trust and sustain growth in the peripheral DCB catheter space.

Actionable strategies to align portfolios, supply chains, and partnerships with evolving DCB clinical and economic realities

Industry leaders navigating the peripheral DCB catheter domain must translate complex clinical and economic drivers into concrete, actionable strategies. One priority is to deepen engagement with key application areas-below-the-knee interventions, dialysis access maintenance, and femoropopliteal procedures-by tailoring product features, training programs, and evidence generation to the realities of each setting. For example, specialized balloon profiles and education focused on pedal arch and tibial artery intervention can help clinicians manage extremely small, diseased vessels, while targeted support for arteriovenous fistula and arteriovenous graft interventions can position DCBs as central tools in long-term dialysis access management.

Another actionable recommendation is to calibrate portfolio strategy around coating type. Organizations with strong paclitaxel-based platforms should continue to reinforce their value proposition through long-term outcomes data, patient subgroup analyses, and health-economic studies that demonstrate reduced reintervention and hospitalization. At the same time, leaders should assess whether and how to incorporate sirolimus-coated balloons, either through internal development or partnerships, to address evolving clinician preferences and regulatory trends. Maintaining a thoughtful balance between established paclitaxel offerings and emerging sirolimus alternatives can provide resilience against shifts in clinical guidelines or payer policies.

Commercial strategy must likewise adapt to the differentiated needs of end users. Hospitals, particularly large tertiary centers, require comprehensive support for complex cases, including access to a full suite of peripheral tools, advanced training, and on-site clinical specialists. Ambulatory surgical centers and specialty clinics, by contrast, often prioritize efficiency, predictable procedure times, and cost control. Industry leaders should design service models that address these varied priorities, such as streamlined consignment programs for high-volume centers, or flexible purchasing arrangements for clinics that are gradually expanding their DCB case mix.

Given growing attention to supply resilience and tariff risk, organizations should also prioritize supply chain diversification and manufacturing agility. Actionable steps include qualifying multiple suppliers for critical components, evaluating regional manufacturing or assembly options, and implementing robust demand forecasting that accounts for fluctuating procedural volumes and policy changes. These measures can mitigate the impact of trade disruptions and help ensure uninterrupted supply for below-the-knee, femoropopliteal, and dialysis access procedures, which often involve vulnerable patient populations.

In parallel, strengthening collaboration with payers and policymakers will be essential. Leaders can support the development of reimbursement pathways that recognize the long-term value of DCB therapies by contributing high-quality real-world data and health-economic analyses. Engaging in multi-stakeholder initiatives aimed at improving limb preservation and dialysis access outcomes can reinforce the role of DCBs within comprehensive care programs. When such collaborations demonstrate reduced amputations, fewer access failures, or lower readmission rates, they provide a compelling case for sustained or enhanced coverage.

Finally, organizations should embed continuous learning into their market approach. This includes investing in data analytics to monitor utilization patterns, outcomes, and customer feedback across regions and facilities, and using these insights to refine training, product design, and commercial messaging. Regularly revisiting strategic assumptions in light of new clinical evidence, regulatory developments, and competitive actions allows leaders to respond proactively rather than reactively, ensuring that their DCB strategies remain aligned with the evolving needs of clinicians and patients.

Robust multi-source research methodology integrating clinical, regulatory, and competitive intelligence on DCB catheters

The research methodology underlying this executive analysis integrates multiple complementary approaches to capture the complexity of the peripheral DCB catheter environment. A structured review of peer-reviewed clinical literature forms the foundation, focusing on studies involving peripheral arterial disease, below-the-knee revascularization, femoropopliteal interventions, and dialysis access maintenance. Particular attention is given to trials and registries evaluating paclitaxel-coated and sirolimus-coated balloons, with analysis of endpoints such as primary patency, target lesion revascularization, limb salvage, and access circuit durability. This evidence base supports a nuanced understanding of how coating technologies perform across lesion types and patient cohorts.

In addition to clinical data, the methodology incorporates systematic examination of regulatory and policy developments in major regions, including the Americas, Europe, Middle East, Africa, and Asia-Pacific. Publicly available regulatory documents, health technology assessments, and reimbursement guidelines are evaluated to understand approval pathways, safety expectations, and coverage conditions for DCB devices. This perspective helps illuminate how differences in regulatory philosophy and healthcare financing influence technology adoption and competitive behavior in hospitals, ambulatory surgical centers, and specialty clinics.

Expert perspectives supplement published sources. Interviews, panel discussions, and conference proceedings involving interventional cardiologists, vascular surgeons, interventional radiologists, and nephrologists provide real-world insights into procedural trends, practice variations, and unmet needs. These qualitative inputs are particularly valuable for understanding how clinicians approach complex segments such as chronic total occlusion, in-stent restenosis, pedal arch disease, and recurrent arteriovenous fistula or arteriovenous graft stenosis. They also shed light on how care delivery is shifting toward outpatient and office-based settings, and how these shifts affect device selection and utilization.

The methodology further integrates analysis of corporate disclosures, product documentation, and publicly available financial and operational information from key industry participants. These sources inform assessments of portfolio strategies, coating technology pipelines, manufacturing capabilities, and commercial approaches, including the use of direct sales versus distributor channels. By triangulating information from clinical, regulatory, and corporate domains, the analysis builds a coherent picture of how innovation and competition are unfolding across the DCB landscape.

To ensure robustness, the research process relies on cross-validation between data types. For example, trends observed in clinical adoption are checked against distributor feedback and procurement practices where possible, while regulatory changes are evaluated in the context of reported shifts in product launches or supply arrangements. Continuous monitoring of emerging publications, conference data, and policy announcements allows the methodology to reflect current developments and evolving consensus. Throughout, the emphasis remains on deriving actionable, evidence-informed insights rather than speculative projections, enabling stakeholders to anchor strategic decisions in a clear and verifiable understanding of the peripheral DCB catheter ecosystem.

Converging clinical, regulatory, and economic forces underscore the strategic importance of peripheral DCB catheters

Peripheral drug-coated balloon catheters have progressed from specialist tools to central components of modern peripheral arterial and dialysis access management, underpinned by a growing body of clinical evidence and continuous technological refinement. Their unique ability to combine mechanical luminal gain with localized drug delivery offers a compelling solution to the persistent challenge of restenosis, particularly in complex anatomical territories such as below-the-knee arteries, femoropopliteal segments, and arteriovenous access circuits. As clinicians and health systems intensify their focus on limb preservation, dialysis access durability, and reduced need for repeat interventions, DCBs occupy an increasingly strategic role in treatment algorithms.

At the same time, the ecosystem in which these devices operate is becoming more intricate. Diverging regulatory expectations, evolving safety perceptions, and differentiated reimbursement frameworks across regions are reshaping how and where DCBs are de

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Peripheral DCB Catheter Market, by Coating Type

  • 8.1. Paclitaxel Coated
  • 8.2. Sirolimus Coated

9. Peripheral DCB Catheter Market, by Application Area

  • 9.1. Below Knee Intervention
    • 9.1.1. Pedal Arch Intervention
    • 9.1.2. Tibial Artery Intervention
  • 9.2. Dialysis Access Maintenance
    • 9.2.1. Arteriovenous Fistula
    • 9.2.2. Arteriovenous Graft
  • 9.3. Femoropopliteal Intervention
    • 9.3.1. Chronic Total Occlusion
    • 9.3.2. De Novo Lesions
    • 9.3.3. In-Stent Restenosis

10. Peripheral DCB Catheter Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Hospitals
  • 10.3. Specialty Clinics

11. Peripheral DCB Catheter Market, by Distribution Channel

  • 11.1. Direct Sales
  • 11.2. Distributor

12. Peripheral DCB Catheter Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Peripheral DCB Catheter Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Peripheral DCB Catheter Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Peripheral DCB Catheter Market

16. China Peripheral DCB Catheter Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Acotec Scientific Co., Ltd.
  • 17.6. Alea Medical GmbH
  • 17.7. B. Braun Melsungen AG
  • 17.8. Becton, Dickinson and Company
  • 17.9. Biotronik SE & Co. KG
  • 17.10. Boston Scientific Corporation
  • 17.11. Cardionovum GmbH
  • 17.12. CeloNova BioSciences, Inc.
  • 17.13. Concept Medical, Inc.
  • 17.14. Cook Medical LLC
  • 17.15. Cordis US Corp.
  • 17.16. Hexacath Limited
  • 17.17. Koninklijke Philips N.V.
  • 17.18. Lepu Medical Technology (Beijing) Co., Ltd.
  • 17.19. Medtronic plc
  • 17.20. Meril Life Sciences Pvt. Ltd.
  • 17.21. Mermaid Medical AS
  • 17.22. MicroPort Medical (Group) Co., Ltd.
  • 17.23. OrbusNeich Medical Group Holdings Limited
  • 17.24. QT Vascular Ltd.
  • 17.25. Reflow Medical, Inc.
  • 17.26. Spectranetics Corporation
  • 17.27. Svelte Medical Systems, Inc.
  • 17.28. Terumo Corporation
  • 17.29. Zhejiang Barty Medical Technology Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PERIPHERAL DCB CATHETER MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PERIPHERAL DCB CATHETER MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY COATING TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY APPLICATION AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES PERIPHERAL DCB CATHETER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA PERIPHERAL DCB CATHETER MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY PACLITAXEL COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY PACLITAXEL COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY PACLITAXEL COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY SIROLIMUS COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY SIROLIMUS COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY SIROLIMUS COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY BELOW KNEE INTERVENTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY BELOW KNEE INTERVENTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY BELOW KNEE INTERVENTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY BELOW KNEE INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY PEDAL ARCH INTERVENTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY PEDAL ARCH INTERVENTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY PEDAL ARCH INTERVENTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY TIBIAL ARTERY INTERVENTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY TIBIAL ARTERY INTERVENTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY TIBIAL ARTERY INTERVENTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY DIALYSIS ACCESS MAINTENANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY DIALYSIS ACCESS MAINTENANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY DIALYSIS ACCESS MAINTENANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY DIALYSIS ACCESS MAINTENANCE, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY ARTERIOVENOUS FISTULA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY ARTERIOVENOUS FISTULA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY ARTERIOVENOUS FISTULA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY ARTERIOVENOUS GRAFT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY ARTERIOVENOUS GRAFT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY ARTERIOVENOUS GRAFT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY FEMOROPOPLITEAL INTERVENTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY FEMOROPOPLITEAL INTERVENTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY FEMOROPOPLITEAL INTERVENTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY FEMOROPOPLITEAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY CHRONIC TOTAL OCCLUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY CHRONIC TOTAL OCCLUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY CHRONIC TOTAL OCCLUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY DE NOVO LESIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY DE NOVO LESIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY DE NOVO LESIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY IN-STENT RESTENOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY IN-STENT RESTENOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY IN-STENT RESTENOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY DISTRIBUTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY DISTRIBUTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY DISTRIBUTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS PERIPHERAL DCB CATHETER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS PERIPHERAL DCB CATHETER MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS PERIPHERAL DCB CATHETER MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS PERIPHERAL DCB CATHETER MARKET SIZE, BY BELOW KNEE INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS PERIPHERAL DCB CATHETER MARKET SIZE, BY DIALYSIS ACCESS MAINTENANCE, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS PERIPHERAL DCB CATHETER MARKET SIZE, BY FEMOROPOPLITEAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS PERIPHERAL DCB CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS PERIPHERAL DCB CATHETER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA PERIPHERAL DCB CATHETER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA PERIPHERAL DCB CATHETER MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA PERIPHERAL DCB CATHETER MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA PERIPHERAL DCB CATHETER MARKET SIZE, BY BELOW KNEE INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA PERIPHERAL DCB CATHETER MARKET SIZE, BY DIALYSIS ACCESS MAINTENANCE, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA PERIPHERAL DCB CATHETER MARKET SIZE, BY FEMOROPOPLITEAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA PERIPHERAL DCB CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA PERIPHERAL DCB CATHETER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA PERIPHERAL DCB CATHETER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA PERIPHERAL DCB CATHETER MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA PERIPHERAL DCB CATHETER MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA PERIPHERAL DCB CATHETER MARKET SIZE, BY BELOW KNEE INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA PERIPHERAL DCB CATHETER MARKET SIZE, BY DIALYSIS ACCESS MAINTENANCE, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA PERIPHERAL DCB CATHETER MARKET SIZE, BY FEMOROPOPLITEAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA PERIPHERAL DCB CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA PERIPHERAL DCB CATHETER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL DCB CATHETER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL DCB CATHETER MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL DCB CATHETER MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL DCB CATHETER MARKET SIZE, BY BELOW KNEE INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL DCB CATHETER MARKET SIZE, BY DIALYSIS ACCESS MAINTENANCE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL DCB CATHETER MARKET SIZE, BY FEMOROPOPLITEAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL DCB CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL DCB CATHETER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE PERIPHERAL DCB CATHETER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE PERIPHERAL DCB CATHETER MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE PERIPHERAL DCB CATHETER MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE PERIPHERAL DCB CATHETER MARKET SIZE, BY BELOW KNEE INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE PERIPHERAL DCB CATHETER MARKET SIZE, BY DIALYSIS ACCESS MAINTENANCE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE PERIPHERAL DCB CATHETER MARKET SIZE, BY FEMOROPOPLITEAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE PERIPHERAL DCB CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE PERIPHERAL DCB CATHETER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST PERIPHERAL DCB CATHETER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST PERIPHERAL DCB CATHETER MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST PERIPHERAL DCB CATHETER MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST PERIPHERAL DCB CATHETER MARKET SIZE, BY BELOW KNEE INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST PERIPHERAL DCB CATHETER MARKET SIZE, BY DIALYSIS ACCESS MAINTENANCE, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST PERIPHERAL DCB CATHETER MARKET SIZE, BY FEMOROPOPLITEAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST PERIPHERAL DCB CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST PERIPHERAL DCB CATHETER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA PERIPHERAL DCB CATHETER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA PERIPHERAL DCB CATHETER MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA PERIPHERAL DCB CATHETER MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA PERIPHERAL DCB CATHETER MARKET SIZE, BY BELOW KNEE INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA PERIPHERAL DCB CATHETER MARKET SIZE, BY DIALYSIS ACCESS MAINTENANCE, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA PERIPHERAL DCB CATHETER MARKET SIZE, BY FEMOROPOPLITEAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA PERIPHERAL DCB CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA PERIPHERAL DCB CATHETER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC PERIPHERAL DCB CATHETER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC PERIPHERAL DCB CATHETER MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC PERIPHERAL DCB CATHETER MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC PERIPHERAL DCB CATHETER MARKET SIZE, BY BELOW KNEE INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC PERIPHERAL DCB CATHETER MARKET SIZE, BY DIALYSIS ACCESS MAINTENANCE, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC PERIPHERAL DCB CATHETER MARKET SIZE, BY FEMOROPOPLITEAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC PERIPHERAL DCB CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC PERIPHERAL DCB CATHETER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN PERIPHERAL DCB CATHETER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN PERIPHERAL DCB CATHETER MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN PERIPHERAL DCB CATHETER MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN PERIPHERAL DCB CATHETER MARKET SIZE, BY BELOW KNEE INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN PERIPHERAL DCB CATHETER MARKET SIZE, BY DIALYSIS ACCESS MAINTENANCE, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN PERIPHERAL DCB CATHETER MARKET SIZE, BY FEMOROPOPLITEAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN PERIPHERAL DCB CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN PERIPHERAL DCB CATHETER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. GCC PERIPHERAL DCB CATHETER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GCC PERIPHERAL DCB CATHETER MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. GCC PERIPHERAL DCB CATHETER MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 137. GCC PERIPHERAL DCB CATHETER MARKET SIZE, BY BELOW KNEE INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 138. GCC PERIPHERAL DCB CATHETER MARKET SIZE, BY DIALYSIS ACCESS MAINTENANCE, 2018-2032 (USD MILLION)
  • TABLE 139. GCC PERIPHERAL DCB CATHETER MARKET SIZE, BY FEMOROPOPLITEAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 140. GCC PERIPHERAL DCB CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. GCC PERIPHERAL DCB CATHETER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION PERIPHERAL DCB CATHETER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION PERIPHERAL DCB CATHETER MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION PERIPHERAL DCB CATHETER MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION PERIPHERAL DCB CATHETER MARKET SIZE, BY BELOW KNEE INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION PERIPHERAL DCB CATHETER MARKET SIZE, BY DIALYSIS ACCESS MAINTENANCE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION PERIPHERAL DCB CATHETER MARKET SIZE, BY FEMOROPOPLITEAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION PERIPHERAL DCB CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION PERIPHERAL DCB CATHETER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS PERIPHERAL DCB CATHETER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS PERIPHERAL DCB CATHETER MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS PERIPHERAL DCB CATHETER MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS PERIPHERAL DCB CATHETER MARKET SIZE, BY BELOW KNEE INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS PERIPHERAL DCB CATHETER MARKET SIZE, BY DIALYSIS ACCESS MAINTENANCE, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS PERIPHERAL DCB CATHETER MARKET SIZE, BY FEMOROPOPLITEAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS PERIPHERAL DCB CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS PERIPHERAL DCB CATHETER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. G7 PERIPHERAL DCB CATHETER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. G7 PERIPHERAL DCB CATHETER MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. G7 PERIPHERAL DCB CATHETER MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 161. G7 PERIPHERAL DCB CATHETER MARKET SIZE, BY BELOW KNEE INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 162. G7 PERIPHERAL DCB CATHETER MARKET SIZE, BY DIALYSIS ACCESS MAINTENANCE, 2018-2032 (USD MILLION)
  • TABLE 163. G7 PERIPHERAL DCB CATHETER MARKET SIZE, BY FEMOROPOPLITEAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 164. G7 PERIPHERAL DCB CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. G7 PERIPHERAL DCB CATHETER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. NATO PERIPHERAL DCB CATHETER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. NATO PERIPHERAL DCB CATHETER MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. NATO PERIPHERAL DCB CATHETER MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 169. NATO PERIPHERAL DCB CATHETER MARKET SIZE, BY BELOW KNEE INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 170. NATO PERIPHERAL DCB CATHETER MARKET SIZE, BY DIALYSIS ACCESS MAINTENANCE, 2018-2032 (USD MILLION)
  • TABLE 171. NATO PERIPHERAL DCB CATHETER MARKET SIZE, BY FEMOROPOPLITEAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 172. NATO PERIPHERAL DCB CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. NATO PERIPHERAL DCB CATHETER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL PERIPHERAL DCB CATHETER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES PERIPHERAL DCB CATHETER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES PERIPHERAL DCB CATHETER MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES PERIPHERAL DCB CATHETER MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES PERIPHERAL DCB CATHETER MARKET SIZE, BY BELOW KNEE INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES PERIPHERAL DCB CATHETER MARKET SIZE, BY DIALYSIS ACCESS MAINTENANCE, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES PERIPHERAL DCB CATHETER MARKET SIZE, BY FEMOROPOPLITEAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES PERIPHERAL DCB CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES PERIPHERAL DCB CATHETER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA PERIPHERAL DCB CATHETER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA PERIPHERAL DCB CATHETER MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA PERIPHERAL DCB CATHETER MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA PERIPHERAL DCB CATHETER MARKET SIZE, BY BELOW KNEE INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA PERIPHERAL DCB CATHETER MARKET SIZE, BY DIALYSIS ACCESS MAINTENANCE, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA PERIPHERAL DCB CATHETER MARKET SIZE, BY FEMOROPOPLITEAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA PERIPHERAL DCB CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA PERIPHERAL DCB CATHETER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)